Ondine Biomedical (OBI) investor relations material

Executive summary

• Achieved 18% year-over-year revenue growth in H1 2025, with gross margin up to 65% and over 200,000 patients treated globally, supported by strategic partnerships and commercial expansion in Canada, UK, and EMEA.

• Strategic investments in clinical trials, distributor onboarding, and rollout of next-generation products contributed to margin gains and revenue growth.

• Net loss widened to $12.6 million for H1 2025, with most sales in Canada and a material uncertainty regarding the ability to continue as a going concern.

• Cash and restricted cash at June 30, 2025, totaled $5.6 million, with significant equity raised post-period.

• Accumulated deficit reached $298.0 million as of June 30, 2025.

Financial highlights

• Revenue for H1 2025 reached $1.01 million CAD, up from $0.86 million CAD in H1 2024 (18% YoY increase), with gross margin at $0.66 million CAD (65% of revenue).

• Operating expenses rose to $13.2 million, up 58% year-over-year, mainly due to increased R&D and marketing costs.

• Net loss widened to $12.56 million CAD from $7.76 million CAD year-over-year.

• Net cash flows from financing activities were $5.5 million in H1, with an additional £11 million (~$21 million CAD) raised post-period.

• 41% increase in medical facilities using the product and 100% customer retention rate.

Outlook and guidance

• Expecting sustained revenue growth in the second half of 2025, with ongoing strategic investments in clinical development and commercial expansion.

• Cash runway secured through the end of Q2 2026 following recent funding.

• Management believes existing cash and anticipated financings will support operations for at least the next twelve months, but ongoing need to raise additional funds remains.

• Anticipate rapid rollout in the U.S. post-FDA approval, leveraging existing hospital relationships.

• No specific revenue or hospital increase guidance provided for future years.